Abstract
Renal afferent and efferent sympathetic nerves are involved in the regulation of blood pressure and have a pathophysiological role in hypertension. Renal sympathetic denervation is a novel therapeutic technique for the treatment of patients with resistant hypertension. Clinical trials of renal sympathetic denervation have shown significant reductions in blood pressure in these patients. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk. Conditions that are comorbid with hypertension, such as heart failure and myocardial hypertrophy, obstructive sleep apnoea, atrial fibrillation, renal dysfunction, and metabolic syndrome are closely associated with enhanced sympathetic activity. In experimental models and case–control studies, renal denervation has had beneficial effects on these conditions. Renal denervation could become a commonly used procedure to treat resistant hypertension and chronic diseases associated with enhanced sympathetic activation. Current work is focused on refining the techniques and interventional devices to provide safe and effective renal sympathetic denervation. Controlled studies in patients with mild-to-moderate, nonresistant hypertension and comorbid conditions such as heart failure, diabetes mellitus, sleep apnoea, and arrhythmias are needed to investigate the capability of renal sympathetic denervation to improve cardiovascular outcomes.
Key Points
-
Sympathetic activity has an important role in the pathophysiology of diseases such as systemic hypertension, arrhythmias, metabolic syndrome, and heart failure
-
Signalling between the kidneys and the central sympathetic nervous system is bidirectional and occurs through the renal afferent and efferent nerves
-
Renal sympathetic denervation reduces both renal and central sympathetic activity, as well as blood pressure, in patients with resistant hypertension
-
Clinical and experimental data suggest that modulation of sympathetic activity might also reduce heart rhythm disturbances such as atrial fibrillation and ventricular arrhythmias
-
Reduced left ventricular hypertrophy and improved diastolic function have also been observed in patients after renal denervation, indicating that this technique could be used to treat diastolic heart failure
-
Whether renal denervation can improve other diseases characterized by elevated sympathetic activity, including hyperinsulinaemia, diabetes mellitus, metabolic syndrome, and obstructive sleep apnoea, is currently being investigated
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Esler, M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J. Appl. Physiol. 108, 227–237 (2010).
Ludwig, C. De viribus physicis secretionem urinae adjuvantibus [Latin]. Thesis, University of Marburg (1842).
Dolezel, S. Monoaminergic innervation of the arteries and veins of the kidney observed using fluorescence reaction. Folia Morphol. (Praha) 14, 168–174 (1966).
Ljungqvist, A. & Wagermark, J. The adrenergic innervation of intrarenal glomerular and extra-glomerular circulatory routes. Nephron 7, 218–229 (1970).
Sobotka, P. A. et al. Sympatho-renal axis in chronic disease. Clin. Res. Cardiol. 100, 1049–1057 (2011).
Converse, R. L. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912–1918 (1992).
Campese, V. M. Neurogenic factors and hypertension in chronic renal failure. J. Nephrol. 10, 184–187 (1997).
Krum. H. et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123, 209–215 (2011).
Bello-Reuss, E., Colindres, R. E., Pastoriza-Munoz, E., Mueller, R. A. & Gottschalk, C. W. Effects of acute unilateral renal denervation in the rat. J. Clin. Invest. 56, 208–217 (1975).
Bradley, T. & Hjemdahl, P. Further studies on renal nerve stimulation induced release of noradrenaline and dopamine from the canine kidney in situ. Acta Physiol. Scand. 122, 369–379 (1984).
Oliver, J. A., Pinto, J., Sciacca, R. R. & Cannon, P. J. Basal norepinephrine overflow into the renal vein: effect of renal nerve stimulation. Am. J. Physiol. 239, F371–F377 (1980).
Bradley, T. & Hjemdahl, P. Influence of afferent renal nerve activity on contralateral renal overflow of noradrenaline and dopamine to plasma in the dog. Acta Physiol. Scand. 128, 119–120 (1986).
Patel, K. P. & Knuepfer, M. M. Effect of afferent renal nerve stimulation on blood pressure, heart rate and noradrenergic activity in conscious rats. J. Auton. Nerv. Syst. 17, 121–130 (1986).
Rogenes, P. R. Single-unit and multiunit analyses of renorenal reflexes elicited by stimulation of renal chemoreceptors in the rat. J. Auton. Nerv. Syst. 6, 143–156 (1982).
Hering, D. et al. Recent advances in the treatment of hypertension. Expert Rev. Cardiovasc. Ther. 9, 729–744 (2011).
Esler, M., Lambert, G. & Jennings, G. Regional norepinephrine turnover in human hypertension. Clin. Exp. Hypertens. A 11 (Suppl. 1), 75–89 (1989).
Huggett, R. J. et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108, 3097–3101 (2003).
Grassi, G. et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46, 321–325 (2005).
Floras, J. S. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J. Am. Coll. Cardiol. 54, 375–385 (2009).
DiBona, G. F. & Sawin, L. L. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am. J. Physiol. 260 (Pt 2), R298–R305 (1991).
Esler, M. The sympathetic system and hypertension. Am. J. Hypertens. 13 (Pt 2), 99S–105S (2000).
Hausberg, M. et al. Sympathetic nerve activity in end-stage renal disease. Circulation 106, 1974–1979 (2002).
Kassab, S. et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25, 893–897 (1995).
Mancia, G. et al. The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25, 909–920 (2007).
Norman, R. A., Murphy, W. R., Dzielak, D. J., Khraibi, A. A. & Carroll, R. G. Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 6, 622–626 (1984).
O'Hagan, K. P., Thomas, G. D. & Zambraski, E. J. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am. J. Hypertens. 3, 62–64 (1990).
Chinushi, M. et al. Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension 61, 450–456 (2013).
Page, I. H. The effect on renal efficiency of lowering arterial blood pressure in cases of essential hypertension and nephritis. J. Clin. Invest. 13, 909–915 (1934).
Page, I. H. & Heuer, G. J. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J. Clin. Invest. 14, 27–30 (1935).
Smithwick, R. H. & Thompson, J. E. Splanchnicectomy for essential hypertension; results in 1,266 cases. J. Am. Med. Assoc. 152, 1501–1504 (1953).
Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105–1187 (2007).
Sarafidis, P. A. & Bakris, G. L. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 52, 1749–1757 (2008).
de la Sierra, A. et al. Clinical features of 8,295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57, 898–902 (2011).
Kumbhani, D. J. et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur. Heart J. 34, 1204–1214 (2013).
Daugherty, S. L. et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125, 1635–1642 (2012).
Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).
Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57, 911–917 (2011).
Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E. & Esler, M. D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361, 932–934 (2009).
Symplicity HTN-2 Investigators et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Esler, M. D. et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126, 2976–2982 (2012).
Rippy, M. K. et al. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin. Res. Cardiol. 100, 1095–1101 (2011).
Persu, A., Renkin, J., Thijs, L. & Staessen, J. A. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 60, 596–606 (2012).
Doumas, M., Faselis, C., Kokkinos, P., Tsioufis, C. & Papademetriou, V. Clinical studies of renal nerve ablation. Unanswered questions for its efficacy and safety. Curr. Clin. Pharmacol. (in press).
Mancia, G. & Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J. Hypertens. 22, 435–445 (2004).
Doumas, M., Anyfanti, P. & Bakris, G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J. Hypertens. 30, 874–876 (2012).
Vaclavik, J. et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57, 1069–1075 (2011).
Kandzari, D. E. et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 Trial. Clin. Cardiol. 35, 528–535 (2012).
Mahfoud, F. et al. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie [German]. Dtsch. Med. Wochenschr. 136, 2418 (2011).
Schmieder, R. E. et al. ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J. Hypertens. 30, 837–841 (2012).
Pathak, A. et al. Expert consensus: renal denervation for the treatment of hypertension. Diagn. Interv. Imaging 93, 386–394 (2012).
Mahfoud, F. et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/eht154.
Kaltenbach, B. et al. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter. Cardiovasc. Interv. 81, 335–339 (2013).
Atherton, D. S., Deep, N. L. & Mendelsohn, F. O. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin. Anat. 25, 628–633 (2012).
Kaltenbach, B. et al. Renal artery stenosis after renal sympathetic denervation. J. Am. Coll. Cardiol. 60, 2694–2695 (2012).
Vonend, O., Antoch, G., Rump, L. C. & Blondin, D. Secondary rise in blood pressure after renal denervation. Lancet 380, 778 (2012).
Ukena, C., Cremers, B., Ewen, S., Böhm, M. & Mahfoud, F. Response and non-response after renal denervation: who is the ideal candidate? EuroIntervention 9, R54–R57 (2013).
Pokushalov, E. et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 60, 1163–1170 (2012).
Ukena, C. et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int. J. Cardiol. http://dx.doi.org/10.1016/j.ijcard.2012.07.027.
Ukena, C. et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J. Am. Coll. Cardiol. 58, 1176–1182 (2011).
Brandt, M. C. et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J. Am. Coll. Cardiol. 60, 1956–1965 (2012).
Levy, M. N. & Zieske, H. Autonomic control of cardiac pacemaker activity and atrioventricular transmission. J. Appl. Physiol. 27, 465–470 (1969).
Gillman, M. W., Kannel, W. B., Belanger, A. & D'Agostino, R. B. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am. Heart J. 125, 1148–1154 (1993).
Shaper, A. G., Wannamethee, G., Macfarlane, P. W. & Walker, M. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br. Heart J. 70, 49–55 (1993).
Böhm, M. et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376, 886–894 (2010).
Reil, J. C. et al. Heart rate reduction in cardiovascular disease and therapy. Clin. Res. Cardiol. 100, 11–19 (2011).
Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885 (2010).
Böhm, M. et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 102, 11–22 (2013).
Shephard, R. J., Berridge, M., Montelpare, W., Daniel, J. V. & Flowers, J. F. Exercise compliance of elderly volunteers. J. Sports Med. Phys. Fitness 27, 410–418 (1987).
Fagard, R. H., Pardaens, K., Staessen, J. A. & Thijs, L. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. Hypertension 28, 31–36 (1996).
Filipovsky, J., Ducimetiere, P. & Safar, M. E. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 20, 333–339 (1992).
Hashimoto, M. et al. Abnormal systolic blood pressure response during exercise recovery in patients with angina pectoris. J. Am. Coll. Cardiol. 22, 659–664 (1993).
Laukkanen, J. A. et al. Systolic blood pressure during recovery from exercise and the risk of acute myocardial infarction in middle-aged men. Hypertension 44, 820–825 (2004).
Doumas, M. & Douma, S. Renal sympathetic denervation: the jury is still out. Lancet 376, 1878–1880 (2010).
Laurent, S. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37, 1236–1241 (2001).
Weber, T. et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109, 184–189 (2004).
Sutton-Tyrrell, K. et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111, 3384–3390 (2005).
Williams, B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113, 1213–1225 (2006).
Chen, C. H. et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 25, 1034–1041 (1995).
Hasking, G. J. et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73, 615–621 (1986).
Gheorghiade, M., Colucci, W. S. & Swedberg, K. β-blockers in chronic heart failure. Circulation 107, 1570–1575 (2003).
Udelson, J. E. Ventricular remodeling in heart failure and the effect of β-blockade. Am. J. Cardiol. 93, 43B–48B (2004).
Francis, G. S. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729 (1990).
DiBona, G. F. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R633–R641 (2005).
Esler, M., Jennings, G. & Lambert, G. Noradrenaline release and the pathophysiology of primary human hypertension. Am. J. Hypertens. 2, 140S–146S (1989).
Jessup, M. & Costanzo, M. R. The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J. Am. Coll. Cardiol. 53, 597–599 (2009).
Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B. & Ho, K. K. The progression from hypertension to congestive heart failure. JAMA 275, 1557–1562 (1996).
Aeschbacher, B. C. et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am. J. Hypertens. 14, 106–113 (2001).
Villarreal, D., Freeman, R. H., Johnson, R. A. & Simmons, J. C. Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am. J. Physiol. 266, R1599–R1604 (1994).
Masaki, H., Imaizumi, T., Harasawa, Y. & Takeshita, A. Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am. J. Physiol. 267, H92–H99 (1994).
Clayton, S. C., Haack, K. K. & Zucker, I. H. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am. J. Physiol. Renal Physiol. 300, F31–F39 (2011).
Brandt, M. C. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59, 901–909 (2012).
McMurray, J. J. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787–1847 (2012).
Zile, M. R. & Little, W. C. Effects of autonomic modulation: more than just blood pressure. J. Am. Coll. Cardiol. 59, 910–912 (2012).
Davies, J. E. et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int. J. Cardiol. 162, 189–192 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Kanagala, R. et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 107, 2589–2594 (2003).
Jongnarangsin, K. et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 19, 668–672 (2008).
Peppard, P. E., Young, T., Palta, M. & Skatrud, J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342, 1378–1384 (2000).
Logan, A. G. et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J. Hypertens. 19, 2271–2277 (2001).
Schotten, U., Verheule, S., Kirchhof, P. & Goette, A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91, 265–325 (2011).
Linz, D., Schotten, U., Neuberger, H. R., Bohm. M. & Wirth, K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm 8, 1436–1443 (2011).
Linz, D. et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 60, 172–178 (2012).
Linz, D. et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension 61, 225–231 (2013).
Witkowski, A. et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58, 559–565 (2011).
Parish, J. M. & Somers, V. K. Obstructive sleep apnea and cardiovascular disease. Mayo Clin. Proc. 79, 1036–1046 (2004).
Reil, J. C. et al. Aldosterone promotes atrial fibrillation. Eur. Heart J. 33, 2098–2108 (2012).
Neuberger, H. R. et al. Procollagen propeptides: serum markers for atrial fibrosis? Clin. Res. Cardiol. 101, 655–661 (2012).
Lown, B. & Verrier, R. L. Neural activity and ventricular fibrillation. N. Engl. J. Med. 294, 1165–1170 (1976).
Schwartz, P. J. et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 109, 1826–1833 (2004).
Conceicao-Souza, G. E. et al. Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study. Eur. J. Heart Fail. 14, 1366–1373 (2012).
Wilde, A. A. et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N. Engl. J. Med. 358, 2024–2029 (2008).
Ukena, C. et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin. Res. Cardiol. 101, 63–67 (2012).
Ruilope, L. M. & Bakris, G. L. Renal function and target organ damage in hypertension. Eur. Heart J. 32, 1599–1604 (2011).
Schmieder, R. E. et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin. Res. Cardiol. 96, 247–257 (2007).
Mahfoud, F. et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60, 419–424 (2012).
Schmieder, R. E. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22, 1353–1364 (2011).
Rump, L. C., Amann, K., Orth, S. & Ritz, E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol. Dial. Transplant. 15, 1735–1738 (2000).
Robertson, D., Krantz, S. B. & Biaggioni, I. The anemia of microgravity and recumbency: role of sympathetic neural control of erythropoietin production. Acta Astronaut. 33, 137–141 (1994).
Hering, D. et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23, 1250–1257 (2012).
Holecki, M., Dulawa, J. & Chudek, J. Resistant hypertension in visceral obesity. Eur. J. Intern. Med. 23, 643–648 (2012).
Huang, W. C., Fang, T. C. & Cheng, J. T. Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats. Hypertension 32, 249–254 (1998).
Mahfoud, F. et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123, 1940–1946 (2011).
Redon, J. et al. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J. Hypertens. 29, 1633–1640 (2011).
Schlaich, M. P. et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens. 29, 991–996 (2011).
Geisler, B. P. et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J. Am. Coll. Cardiol. 60, 1271–1277 (2012).
Acknowledgements
M. Böhm's and C. Ukena's research is supported by the Deutsche Forschungsgemeinschaft (DFG, KFO 196). D. Linz's and F. Mahfoud's research is supported by the Deutsche Hochdruckliga. All the authors' research is supported by the German Cardiac Society.
Author information
Authors and Affiliations
Contributions
All the authors researched the data for the article, provided substantial contributions to discussions of its content, and undertook review and/or editing of the manuscript before submission. M. Böhm wrote the article.
Corresponding author
Ethics declarations
Competing interests
M. Böhm and F. Mahfoud declare that they have received grant or research support from Cordis, Medtronic Ardian, and St. Jude Medical. All authors declare that their institution has received scientific grants from Bayer, Boehringer Ingelheim, Medtronic, Pfizer, Servier, and St. Jude Medical.
Rights and permissions
About this article
Cite this article
Böhm, M., Linz, D., Urban, D. et al. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol 10, 465–476 (2013). https://doi.org/10.1038/nrcardio.2013.89
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.89
This article is cited by
-
A systematic review of the effects of transcutaneous auricular vagus nerve stimulation on baroreflex sensitivity and heart rate variability in healthy subjects
Clinical Autonomic Research (2023)
-
Interventionelle Therapie der arteriellen Hypertonie
CardioVasc (2023)
-
Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome
Basic Research in Cardiology (2022)
-
Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea)
Journal of Human Hypertension (2016)
-
Carotid baroreflex activation therapy for resistant hypertension
Nature Reviews Cardiology (2015)